UCB has presented the first pooled data analysis from phase 3 trials of its bimekizumab treatment for moderate to severe hidradenitis suppurativa at the European Academy of Dermatology and Venereology (EADV) Congress. The analysis showed the treatment led to clinically important improvements and a large percentage of patients who achieved a high skin response after 16 weeks maintained their response up to 48 weeks.
![](https://healsecurity.com/wp-content/uploads/2024/09/cdc-issues-warning-over-recalled-eggs-sold-in-three-states.jpg)
CDC issues warning over recalled eggs sold in three states
The Centers for Disease Control and Prevention (CDC) has issued a warning against recalled eggs linked to 24 hospitalizations due to salmonella infection. The eggs,